Beta Bionics, Inc.

BBNX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BBNX stands at 828.5M. In comparison, LH has a market cap of 21.8B. Regarding current trading prices, BBNX is priced at $19.11, while LH trades at $261.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BBNX currently has a P/E ratio of -11.65, whereas LH's P/E ratio is 30.15. In terms of profitability, BBNX's ROE is -0.57%, compared to LH's ROE of +0.09%. Regarding short-term risk, BBNX is more volatile compared to LH. This indicates potentially higher risk in terms of short-term price fluctuations for BBNX.

BBNX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BBNX stands at 828.5M. In comparison, NVST has a market cap of 3.1B. Regarding current trading prices, BBNX is priced at $19.11, while NVST trades at $18.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BBNX currently has a P/E ratio of -11.65, whereas NVST's P/E ratio is -2.82. In terms of profitability, BBNX's ROE is -0.57%, compared to NVST's ROE of -0.37%. Regarding short-term risk, BBNX is more volatile compared to NVST. This indicates potentially higher risk in terms of short-term price fluctuations for BBNX.

BBNX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BBNX stands at 828.5M. In comparison, CON has a market cap of 2.7B. Regarding current trading prices, BBNX is priced at $19.11, while CON trades at $21.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BBNX currently has a P/E ratio of -11.65, whereas CON's P/E ratio is 15.66. In terms of profitability, BBNX's ROE is -0.57%, compared to CON's ROE of +0.34%. Regarding short-term risk, BBNX is more volatile compared to CON. This indicates potentially higher risk in terms of short-term price fluctuations for BBNX.

BBNX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BBNX stands at 828.5M. In comparison, KDLY has a market cap of 83.5M. Regarding current trading prices, BBNX is priced at $19.11, while KDLY trades at $13.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BBNX currently has a P/E ratio of -11.65, whereas KDLY's P/E ratio is -19.00. In terms of profitability, BBNX's ROE is -0.57%, compared to KDLY's ROE of -1.46%. Regarding short-term risk, BBNX is less volatile compared to KDLY. This indicates potentially lower risk in terms of short-term price fluctuations for BBNX.

BBNX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BBNX stands at 828.5M. In comparison, NEUE has a market cap of 61.2M. Regarding current trading prices, BBNX is priced at $19.11, while NEUE trades at $6.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BBNX currently has a P/E ratio of -11.65, whereas NEUE's P/E ratio is -0.31. In terms of profitability, BBNX's ROE is -0.57%, compared to NEUE's ROE of +0.22%. Regarding short-term risk, BBNX is more volatile compared to NEUE. This indicates potentially higher risk in terms of short-term price fluctuations for BBNX.